<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain</journal-id>
<journal-id journal-id-type="publisher-id">brainj</journal-id>
<journal-title-group>
<journal-title>Brain</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-8950</issn>
<issn pub-type="epub">1460-2156</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27604308</article-id>
<article-id pub-id-type="pmc">5091046</article-id>
<article-id pub-id-type="doi">10.1093/brain/aww221</article-id>
<article-id pub-id-type="publisher-id">aww221</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Reid</surname>
<given-names>Emma S.</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF1">aww221-1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Papandreou</surname>
<given-names>Apostolos</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF1">aww221-1</xref>
<xref ref-type="aff" rid="aww221-AFF2">aww221-2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Drury</surname>
<given-names>Suzanne</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF3">aww221-3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boustred</surname>
<given-names>Christopher</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF3">aww221-3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yue</surname>
<given-names>Wyatt W.</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF4">aww221-4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wedatilake</surname>
<given-names>Yehani</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF1">aww221-1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beesley</surname>
<given-names>Clare</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF3">aww221-3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jacques</surname>
<given-names>Thomas S.</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF5">aww221-5</xref>
<xref ref-type="aff" rid="aww221-AFF6">aww221-6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Anderson</surname>
<given-names>Glenn</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF5">aww221-5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abulhoul</surname>
<given-names>Lara</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF7">aww221-7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Broomfield</surname>
<given-names>Alex</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF7">aww221-7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cleary</surname>
<given-names>Maureen</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF7">aww221-7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grunewald</surname>
<given-names>Stephanie</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF1">aww221-1</xref>
<xref ref-type="aff" rid="aww221-AFF7">aww221-7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Varadkar</surname>
<given-names>Sophia M.</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF2">aww221-2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lench</surname>
<given-names>Nick</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF3">aww221-3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rahman</surname>
<given-names>Shamima</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF1">aww221-1</xref>
<xref ref-type="aff" rid="aww221-AFF7">aww221-7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gissen</surname>
<given-names>Paul</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF1">aww221-1</xref>
<xref ref-type="aff" rid="aww221-AFF7">aww221-7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Clayton</surname>
<given-names>Peter T.</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF1">aww221-1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mills</surname>
<given-names>Philippa B.</given-names>
</name>
<xref ref-type="aff" rid="aww221-AFF1">aww221-1</xref>
<!--<email>p.mills@ucl.ac.uk</email>-->
</contrib>
</contrib-group>
<aff id="aww221-AFF1"><label>aww221-1</label>1 Genetics and Genomics Medicine Programme, UCL Institute of Child Health, London, UK</aff>
<aff id="aww221-AFF2"><label>aww221-2</label>2 Neurology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK</aff>
<aff id="aww221-AFF3"><label>aww221-3</label>3 North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK</aff>
<aff id="aww221-AFF4"><label>aww221-4</label>4 Structural Genomics Consortium, University of Oxford, Oxford, UK</aff>
<aff id="aww221-AFF5"><label>aww221-5</label>5 Histopathology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK</aff>
<aff id="aww221-AFF6"><label>aww221-6</label>6 Developmental Biology and Cancer Programme, UCL Institute of Child Health, London, UK</aff>
<aff id="aww221-AFF7"><label>aww221-7</label>7 Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK</aff>
<author-notes>
<corresp id="aww221-COR1">Correspondence to: Dr Philippa B. Mills, PhD, Genetics and Genomic Medicine Programme, UCL Institute of Child Health, 30 Guildford Street, London, WC1N 1EH, UK E-mail: <email>p.mills@ucl.ac.uk</email></corresp>
<fn id="FM1">
<p>*These authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date iso-8601-date="2016-09-06" pub-type="epub">
<day>06</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>06</day>
<month>9</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<!-- oupReleaseDelayRemoved from OA Article (10.1093/brain/aww221aww221Reports1030Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypesReidEmma S.PapandreouApostolosDrurySuzanneBoustredChristopherYueWyatt W.WedatilakeYehaniBeesleyClareJacquesThomas S.AndersonGlennAbulhoulLaraBroomfieldAlexClearyMaureenGrunewaldStephanieVaradkarSophia M.LenchNickRahmanShamimaGissenPaulClaytonPeter T.MillsPhilippa B.p.mills@ucl.ac.uk1 Genetics and Genomics Medicine Programme, UCL Institute of Child Health, London, UK2 Neurology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK3 North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK4 Structural Genomics Consortium, University of Oxford, Oxford, UK5 Histopathology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK6 Developmental Biology and Cancer Programme, UCL Institute of Child Health, London, UK7 Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UKCorrespondence to: Dr Philippa B. Mills, PhD, Genetics and Genomic Medicine Programme, UCL Institute of Child Health, 30 Guildford Street, London, WC1N 1EH, UK E-mail: p.mills@ucl.ac.uk*These authors contributed equally to this work.11201601112016060920161391128442854Supplementary Data224201618620161472016&#x000a9; The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain.2016This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.Targeted gene panels can be used to establish molecular diagnoses in paediatric cohorts. Reid et al. report that this approach is accurate, efficient and can be preferred to whole-exome or genome sequencing for patients with neurological symptomatology and clues suggestive of an inherited metabolic disorder.
          Targeted gene panels can be used to establish molecular diagnoses in paediatric cohorts. Reid et al. report that this approach is accurate, efficient and can be preferred to whole-exome or genome sequencing for patients with neurological symptomatology and clues suggestive of an inherited metabolic disorder.
        Neurometabolic disorders are markedly heterogeneous, both clinically and genetically, and are characterized by variable neurological dysfunction accompanied by suggestive neuroimaging or biochemical abnormalities. Despite early specialist input, delays in diagnosis and appropriate treatment initiation are common. Next-generation sequencing approaches still have limitations but are already enabling earlier and more efficient diagnoses in these patients. We designed a gene panel targeting 614 genes causing inborn errors of metabolism and tested its diagnostic efficacy in a paediatric cohort of 30 undiagnosed patients presenting with variable neurometabolic phenotypes. Genetic defects that could, at least partially, explain observed phenotypes were identified in 53% of cases. Where biochemical abnormalities pointing towards a particular gene defect were present, our panel identified diagnoses in 89% of patients. Phenotypes attributable to defects in more than one gene were seen in 13% of cases. The ability of in silico tools, including structure-guided prediction programmes to characterize novel missense variants were also interrogated. Our study expands the genetic, clinical and biochemical phenotypes of well-characterized (POMGNT1, TPP1) and recently identified disorders (PGAP2, ACSF3, SERAC1, AFG3L2, DPYS). Overall, our panel was accurate and efficient, demonstrating good potential for applying similar approaches to clinically and biochemically diverse neurometabolic disease cohorts.neurometabolic disordersinborn errors of metabolismheterogeneitynext-generation sequencinggene panelWellcome Trust10.13039/100004440V2516 and V1254Action Medical Research (AMR) and British Paediatric Neurology Association (BPNA)University College LondonNational Institute for Health Research Biomedical Research CentreNHS Foundation Trust and University College London) -->
<volume>139</volume>
<issue>11</issue>
<fpage>2844</fpage>
<lpage>2854</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>4</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>18</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>7</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri xlink:href="aww221.pdf"></self-uri>
<abstract abstract-type="teaser">
<p>Targeted gene panels can be used to establish molecular diagnoses in paediatric cohorts. Reid <italic>et al</italic>. report that this approach is accurate, efficient and can be preferred to whole-exome or genome sequencing for patients with neurological symptomatology and clues suggestive of an inherited metabolic disorder.</p>
</abstract>
<abstract abstract-type="graphical">
<p>
<fig fig-type="featured" id="fig1g" orientation="portrait" position="float"><caption><p>Targeted gene panels can be used to establish molecular diagnoses in paediatric cohorts. Reid <italic>et al</italic>. report that this approach is accurate, efficient and can be preferred to whole-exome or genome sequencing for patients with neurological symptomatology and clues suggestive of an inherited metabolic disorder.</p></caption><graphic xlink:href="aww221fig1g"></graphic></fig>
</p>
</abstract>
<abstract>
<p>Neurometabolic disorders are markedly heterogeneous, both clinically and genetically, and are characterized by variable neurological dysfunction accompanied by suggestive neuroimaging or biochemical abnormalities. Despite early specialist input, delays in diagnosis and appropriate treatment initiation are common. Next-generation sequencing approaches still have limitations but are already enabling earlier and more efficient diagnoses in these patients. We designed a gene panel targeting 614 genes causing inborn errors of metabolism and tested its diagnostic efficacy in a paediatric cohort of 30 undiagnosed patients presenting with variable neurometabolic phenotypes. Genetic defects that could, at least partially, explain observed phenotypes were identified in 53% of cases. Where biochemical abnormalities pointing towards a particular gene defect were present, our panel identified diagnoses in 89% of patients. Phenotypes attributable to defects in more than one gene were seen in 13% of cases. The ability of <italic>in silico</italic> tools, including structure-guided prediction programmes to characterize novel missense variants were also interrogated. Our study expands the genetic, clinical and biochemical phenotypes of well-characterized (<italic>POMGNT1</italic>, <italic>TPP1</italic>) and recently identified disorders (<italic>PGAP2</italic>, <italic>ACSF3</italic>, <italic>SERAC1</italic>, <italic>AFG3L2</italic>, <italic>DPYS</italic>). Overall, our panel was accurate and efficient, demonstrating good potential for applying similar approaches to clinically and biochemically diverse neurometabolic disease cohorts.</p>
</abstract>
<kwd-group kwd-group-type="keywords">
<kwd>neurometabolic disorders</kwd>
<kwd>inborn errors of metabolism</kwd>
<kwd>heterogeneity</kwd>
<kwd>next-generation sequencing</kwd>
<kwd>gene panel</kwd>
</kwd-group>
<funding-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">Wellcome Trust</named-content>
<named-content content-type="funder-identifier">10.13039/100004440</named-content>
</funding-source>
</award-group>
<award-group award-type="grant">
<award-id>V2516 and V1254</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">Action Medical Research (AMR) and British Paediatric Neurology Association (BPNA)</named-content>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">University College London</named-content>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institute for Health Research Biomedical Research Centre</named-content>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">NHS Foundation Trust and University College London</named-content>
</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="11"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Inborn errors of metabolism (IEM) are markedly heterogeneous, both clinically and genetically, with more than 600 genes known to cause disease. In the presence of neurological dysfunction, which is not only common in IEM but also often the most prominent phenotypic feature, these patients are frequently labelled as having ‘probable neurometabolic disease’, especially if suggestive neuroimaging or laboratory findings co-exist. The challenges when diagnosing neurometabolic disorders are largely attributable to the clinical and genetic heterogeneity (including often non-specific or atypical presentations early on in the disease course) and lack of clinical awareness of rare entities. Patients with suspected neurometabolic disease are frequently referred to specialist centres and undergo extensive and often invasive diagnostic testing. Despite this, diagnostic delays or difficulties establishing a definitive diagnosis are commonly encountered, with many such patients attending secondary and tertiary neurology clinics remaining undiagnosed (<xref ref-type="bibr" rid="aww221-B37">Verity <italic>et al.</italic>, 2010</xref>).</p>
<p>Timely diagnosis of neurometabolic disease is crucial, especially for those disorders that are treatable or manageable, with early initiation of treatment often resulting in improved outcomes. Next-generation sequencing (NGS) has revolutionized the diagnostic approach to such conditions (<xref ref-type="bibr" rid="aww221-B21">Nemeth <italic>et al.</italic>, 2013</xref>; <xref ref-type="bibr" rid="aww221-B19">Martin <italic>et al.</italic>, 2014</xref>) and helped to reduce the number of tests required for a diagnosis to be established. However, despite the continuous progress made in the field, there are still limitations to the approach, including access to NGS technology (especially in a non-specialist setting), costs, incomplete coverage of candidate genes and generation of large amounts of data that are difficult to interpret. Whole-exome sequencing (WES) and whole-genome sequencing (WGS) studies are primarily offered either in research laboratories or in a commercial setting, and have not yet been fully integrated into the clinical genetics services of many healthcare systems worldwide. An alternative NGS method, gene panel testing, has recently become available in clinical services and offers targeted testing of candidate genes. An extended genetic panel approach to investigating IEM might be advantageous (<xref ref-type="bibr" rid="aww221-B10">Saudi Mendeliome Group, 2015</xref>) due to reduced times required for data processing and increased coverage depth compared to WES and WGS. Our objective was to investigate the utility of this approach by designing an IEM gene panel and applying it to patients presenting with a wide array of neurometabolic phenotypes. We discuss the panel’s effectiveness in establishing a diagnosis, the clinical implications of its use as well as potential pitfalls of using broad-scale genetic testing. We also consider the predictive value of <italic>in silico</italic> tools commonly used for characterization of novel variants and investigate whether mapping of detected variants to known 3D protein structures can help further elucidate their significance.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec sec-type="subjects">
<title>Patients</title>
<p>This study was approved by the National Research Ethics Service (NRES) Committee London – Bloomsbury (REC reference: 13/LO/0168). We recruited patients from a single UK tertiary centre’s neurometabolic disease clinics presenting with a range of neurological features such as developmental delay, macro or microcephaly, neurological regression, ataxia, epilepsy and/or organomegaly with or without other diagnostic indicators [including suggestive biochemical marker(s) or neuroimaging abnormalities]. All participants had undergone extensive previous investigations including multiple standard and specialized biochemical tests, invasive procedures (e.g. muscle and/or skin biopsy, lumbar puncture) and targeted gene testing but lacked a definitive molecular diagnosis. Thirty patients were included (<xref ref-type="table" rid="aww221-T1 aww221-T2 aww221-T3">Tables 1–3</xref>). First, we recruited 21 patients with suspected IEM but absence of specific clinical findings or biochemical pointers towards a particular disorder. Additionally, we included nine cases where biochemical findings indicated a particular disorder or group of disorders, not only to investigate the utility of this approach in more specific presentations but also because similar biochemical abnormalities could result from mutations in multiple genes. Finally, for panel validation purposes, we additionally recruited 13 patients with a known genetic diagnosis (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1</xref>). Written informed consent was obtained in all cases.
<table-wrap id="aww221-T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical, biochemical and imaging phenotypes in patients who had pathogenic variants identified through gene panel sequencing</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th colspan="1" rowspan="1">Patient</th><th colspan="1" rowspan="1">Age (years)</th><th colspan="1" rowspan="1">Gender</th><th colspan="1" rowspan="1">Primary clinical phenotype</th><th colspan="1" rowspan="1">Other phenotypic features</th><th colspan="1" rowspan="1">Relevant specialist investigations</th><th colspan="1" rowspan="1">MRI head</th><th colspan="1" rowspan="1">Diagnosis</th><th colspan="1" rowspan="1">Gene</th></tr></thead><tbody align="left"><tr><td align="left" colspan="1" rowspan="1">B1</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">Macrocephaly, intermittent squint</td><td align="left" colspan="1" rowspan="1">Short stature, asthma, development unremarkable</td><td align="left" colspan="1" rowspan="1">Elevated 3-methylcrotonylglycine, methylcitrate and 3-hydroxyisovalerate in urine. Normal biotinidase activity</td><td align="left" colspan="1" rowspan="1">Not performed</td><td align="left" colspan="1" rowspan="1">Holocarboxylase synthetase deficiency</td><td align="left" colspan="1" rowspan="1"><italic>HLCS</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">B2</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">Sibling born prematurely and passed away due to hyper-ammonaemia. No clinical concerns</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">Moderately elevated orotic acid in urine between 9-48 µmol/mmol creatinine (ref: 0-5)</td><td align="left" colspan="1" rowspan="1">Not performed</td><td align="left" colspan="1" rowspan="1">Orotic aciduria</td><td align="left" colspan="1" rowspan="1"><italic>UMPS</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">B3</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">At 3 1/2 years: lethargy, vomiting, alkalosis and hyper-ammonaemia Learning and behavioural difficulties</td><td align="left" colspan="1" rowspan="1">Day 2 of life: to lethargy and irritability- presumed sepsis but cultures negative. NH<sub>3</sub> not measured</td><td align="left" colspan="1" rowspan="1">Plasma aminoacids: raised glutamine. Low carbomylphosphate synthase activity in liver biopsy (0.15 mmol/hr/mg protein)</td><td align="left" colspan="1" rowspan="1">Not performed</td><td align="left" colspan="1" rowspan="1">Carbomoyl phosphate synthetase I deficiency</td><td align="left" colspan="1" rowspan="1"><italic>CPS1</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">B4</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">Short stature, obesity, distended abdomen at 3 years</td><td align="left" colspan="1" rowspan="1">Hepatomegaly. No documented learning difficulties</td><td align="left" colspan="1" rowspan="1">Low glycogen debranching enzyme activity of 0.07 µmol/min/g protein (ref: 0.3-3.0)</td><td align="left" colspan="1" rowspan="1">Not performed</td><td align="left" colspan="1" rowspan="1">Glycogen storage disease type III</td><td align="left" colspan="1" rowspan="1"><italic>AGL</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">B5</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">Galactosaemia, picked up through newborn screening, treated early</td><td align="left" colspan="1" rowspan="1">Normal development apart from difficulties in mathematics</td><td align="left" colspan="1" rowspan="1">Low gal-1-P-uridyltransferase activity Elevated galactose-1-phosphate</td><td align="left" colspan="1" rowspan="1">Not performed</td><td align="left" colspan="1" rowspan="1">Galactosaemia</td><td align="left" colspan="1" rowspan="1"><italic>GALT</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">B6</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">Global delay. One of monozygotic twins</td><td align="left" colspan="1" rowspan="1">Hypotonia, brachycephaly, long face</td><td align="left" colspan="1" rowspan="1">Elevated plasma lysine ranging between 439-449 µmol/l (ref: 100-300). Elevated CSF lysine of 67 µmol/l (ref: 10-32)</td><td align="left" colspan="1" rowspan="1">Delayed myelination, lack of white matter bulk</td><td align="left" colspan="1" rowspan="1">Hyperlysinaemia</td><td align="left" colspan="1" rowspan="1"><italic>AASS</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">B7</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">Global delay, epilepsy, one of monozygotic twins</td><td align="left" colspan="1" rowspan="1">Hypotonia, brachycephaly, long face</td><td align="left" colspan="1" rowspan="1">Elevated plasma lysine ranging between 440-780 µmol/l (ref: 100-300). Elevated CSF lysine of 92 µmol/l (ref: 10-32)</td><td align="left" colspan="1" rowspan="1">Not performed</td><td align="left" colspan="1" rowspan="1">Hyperlysinaemia</td><td align="left" colspan="1" rowspan="1"><italic>AASS</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">B8</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">Sensorineural hearing loss, ataxia, neurological regression</td><td align="left" colspan="1" rowspan="1">Scoliosis, constipation</td><td align="left" colspan="1" rowspan="1">Bile acid analysis and skin fibroblast studies suggestive of a peroxisomal biogenesis defect</td><td align="left" colspan="1" rowspan="1">Leukodystrophy</td><td align="left" colspan="1" rowspan="1">Peroxisome biogenesis disorder</td><td align="left" colspan="1" rowspan="1"><italic>PEX6</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">U1</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">Developmental delay, ataxia, horizontal nystagmus</td><td align="left" colspan="1" rowspan="1">Microcephaly, retinal dystrophy</td><td align="left" colspan="1" rowspan="1">CSF: low 5-MTHF and high HVA and BH4. Blood: Elevated prolactin, alanine, intermittently high CK and plasma lactate. Muscle: Normal RCE</td><td align="left" colspan="1" rowspan="1">Normal</td><td align="left" colspan="1" rowspan="1">Muscular dystrophy-dystroglycanopathy</td><td align="left" colspan="1" rowspan="1"><italic>POMGNT1</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">U2</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">Microcephaly, developmental delay</td><td align="left" colspan="1" rowspan="1">Dysplastic kidneys</td><td align="left" colspan="1" rowspan="1">Neonatal lactic acidosis, high plasma triglycerides, elevated urine thymidine and uracil, low plasma urate and detectable tymine</td><td align="left" colspan="1" rowspan="1">Normal</td><td align="left" colspan="1" rowspan="1">Dihydropyrimidinase deficiency</td><td align="left" colspan="1" rowspan="1"><italic>DPYS</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">U3</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">Neonatal jitteriness, developmental delay, autism</td><td align="left" colspan="1" rowspan="1">Joint hypermobility</td><td align="left" colspan="1" rowspan="1">Persistent methylmalonic and malonic aciduria</td><td align="left" colspan="1" rowspan="1">Not performed</td><td align="left" colspan="1" rowspan="1">Combined malonic and methylmalonic aciduria</td><td align="left" colspan="1" rowspan="1"><italic>ACSF3</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">U4</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">Congenital ataxia, diplegia; drop attacks, no obvious EEG correlate</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">Plasma: mildly raised alanine, normal lactate. CSF: low 5-HIAA</td><td align="left" colspan="1" rowspan="1">Abnormal bilateral caudate and lentiform neuclei signal</td><td align="left" colspan="1" rowspan="1">Spinocerebellar ataxia 28 / Autosomal recessive spastic ataxia 5</td><td align="left" colspan="1" rowspan="1"><italic>AFG3L2</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">U5</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">Developmental delay, subsequent regression with progressive dyskinetic movement disorder, dysphagia</td><td align="left" colspan="1" rowspan="1">Sensorineural deafness</td><td align="left" colspan="1" rowspan="1">Raised 3-methylglutaconic acid level with normal 3-methylglutaric levels</td><td align="left" colspan="1" rowspan="1">Basal ganglia high T<sub>2</sub> signal, cerebellar atrophy</td><td align="left" colspan="1" rowspan="1">3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome</td><td align="left" colspan="1" rowspan="1"><italic>SERAC1</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">U6</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">Global severe developmental delay, tonic seizures</td><td align="left" colspan="1" rowspan="1">Multiorgan malformations including VSD, Hirschprung’s. Dysmorphism</td><td align="left" colspan="1" rowspan="1">Recurrent hypoglycaemia; hypogammaglobulinaemia, hyperphosphatasia</td><td align="left" colspan="1" rowspan="1">Dandy-Walker malformation, reduced white matter bulk</td><td align="left" colspan="1" rowspan="1">Hyperphosphatasia with mental retardation syndrome 3</td><td align="left" colspan="1" rowspan="1"><italic>PGAP2</italic></td></tr><tr><td colspan="1" rowspan="2">U7</td><td colspan="1" rowspan="2">6</td><td colspan="1" rowspan="2">M</td><td colspan="1" rowspan="2">Developmental delay, microcephaly, lower limb hyper-reflexia</td><td colspan="1" rowspan="2">No</td><td colspan="1" rowspan="2">Abnormal transferrin isoelectric focusing (type 1 pattern)</td><td colspan="1" rowspan="2">Lack of white matter bulk</td><td colspan="1" rowspan="2">Late infantile neuronal ceroid lipofuscinosis; Hereditary fructose intolerance</td><td align="left" colspan="1" rowspan="1"><italic>TPP1 + ALDOB</italic></td></tr><tr><td align="left" colspan="1" rowspan="1"></td></tr><tr><td align="left" colspan="1" rowspan="1">U8</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">Global developmental delay, Sensorineural hearing loss</td><td align="left" colspan="1" rowspan="1">Neonatal acute liver failure, resolved. Recurrent hypoglycaemia. Recurrent infections</td><td align="left" colspan="1" rowspan="1">Abnormal transferrin isoelectric focusing (type 1 pattern), normal phosphomannomutase and phosphomannisomerase. Low IgA/IgM, normal IgG and lymphocyte subsets</td><td align="left" colspan="1" rowspan="1">Normal</td><td align="left" colspan="1" rowspan="1">Galactose epimerase deficiency</td><td align="left" colspan="1" rowspan="1"><italic>GALE</italic></td></tr></tbody></table><table-wrap-foot><fn id="aww221-TF1"><p>5-HIAA = 5-hydroxyindoleacetic acid; 5-MTHF = 5-methyltetrahydrofolate; BH4 = tetrahydrobiopterin; CK = creatine kinase; F = female; HVA = homovanillic acid; M = male; RCE = respiratory chain enzymes; VSD = ventricular septal defect.</p></fn></table-wrap-foot></table-wrap><table-wrap id="aww221-T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Details of pathogenic variants identified in patients through gene panel sequencing</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th colspan="1" rowspan="1">Patient</th><th colspan="1" rowspan="1">Gene</th><th colspan="1" rowspan="1">Nucleotide change</th><th colspan="1" rowspan="1">Amino acid</th><th colspan="1" rowspan="1">Segregation confirmed</th><th colspan="1" rowspan="1">SIFT</th><th colspan="1" rowspan="1">PolyPhen-2</th><th colspan="1" rowspan="1">CADD score</th><th colspan="1" rowspan="1">Reference</th><th colspan="1" rowspan="1">Clinical phenotype explained</th><th colspan="1" rowspan="1">Biochemical phenotype explained</th></tr></thead><tbody align="left"><tr><td colspan="1" rowspan="3">B1</td><td colspan="1" rowspan="3"><italic>HLCS</italic></td><td colspan="1" rowspan="1">c.2126C&gt;T</td><td colspan="1" rowspan="1">p.Pro709Leu</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Deleterious</td><td colspan="1" rowspan="1">Probably damaging</td><td colspan="1" rowspan="1">20.9</td><td colspan="1" rowspan="1">Novel</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">c.1921G&gt;A</td><td colspan="1" rowspan="1">p.Val641Met</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Deleterious</td><td colspan="1" rowspan="1">Possibly damaging</td><td colspan="1" rowspan="1">24.8</td><td colspan="1" rowspan="1">Novel</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">c.1533dupT</td><td colspan="1" rowspan="1">p.Val512CysfsTer65</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">35.0</td><td colspan="1" rowspan="1">Novel</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">B2</td><td colspan="1" rowspan="1">UMPS</td><td colspan="1" rowspan="1">c.451G&gt;A</td><td colspan="1" rowspan="1">p.Val151Met</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Deleterious</td><td colspan="1" rowspan="1">Probably damaging</td><td colspan="1" rowspan="1">26.7</td><td colspan="1" rowspan="1">Novel</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">B3</td><td colspan="1" rowspan="1">CPS1</td><td colspan="1" rowspan="1">c.1010A&gt;G</td><td colspan="1" rowspan="1">p.His337Arg</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Deleterious</td><td colspan="1" rowspan="1">Probably damaging</td><td colspan="1" rowspan="1">26.3</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="aww221-B2">Aoshima <italic>et al.</italic> 2001</xref></td><td colspan="1" rowspan="1">Yes<sup>c</sup></td><td colspan="1" rowspan="1">Yes<sup>c</sup></td></tr><tr><td colspan="1" rowspan="2">B4</td><td colspan="1" rowspan="2">AGL</td><td colspan="1" rowspan="1">c.2590C&gt;T</td><td colspan="1" rowspan="1">p.Arg864Ter</td><td colspan="1" rowspan="2">No</td><td colspan="1" rowspan="2">-</td><td colspan="1" rowspan="2">-</td><td colspan="1" rowspan="2">38.0</td><td colspan="1" rowspan="2"><xref ref-type="bibr" rid="aww221-B30">Shen <italic>et al.</italic> 1996</xref></td><td colspan="1" rowspan="2">Yes</td><td colspan="1" rowspan="2">Yes</td></tr><tr><td colspan="1" rowspan="1">c.2590C&gt;T</td><td colspan="1" rowspan="1">p.Arg864Ter</td></tr><tr><td colspan="1" rowspan="2">B5</td><td colspan="1" rowspan="2">GALT</td><td colspan="1" rowspan="1">c.563A&gt;G</td><td colspan="1" rowspan="1">p.Gln188Arg</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Deleterious</td><td colspan="1" rowspan="1">Probably damaging</td><td colspan="1" rowspan="1">25.3</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="aww221-B24">Reichardt <italic>et al.</italic> 1991</xref></td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">c.584T&gt;C</td><td colspan="1" rowspan="1">p.Leu195Pro</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Deleterious</td><td colspan="1" rowspan="1">Benign</td><td colspan="1" rowspan="1">26.1</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="aww221-B23">Reichardt <italic>et al.</italic> 1992</xref></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="2">B6</td><td colspan="1" rowspan="2">AASS</td><td colspan="1" rowspan="1">c.965G&gt;A</td><td colspan="1" rowspan="1">p.Arg322His</td><td colspan="1" rowspan="2">No</td><td colspan="1" rowspan="2">Tolerated</td><td colspan="1" rowspan="2">Probably damaging</td><td colspan="1" rowspan="2">29.1</td><td colspan="1" rowspan="2">Novel</td><td colspan="1" rowspan="2">No</td><td colspan="1" rowspan="2">Yes</td></tr><tr><td colspan="1" rowspan="1">c.965G&gt;A</td><td colspan="1" rowspan="1">p.Arg322His</td></tr><tr><td colspan="1" rowspan="2">B7</td><td colspan="1" rowspan="2">AASS</td><td colspan="1" rowspan="1">c.965G&gt;A</td><td colspan="1" rowspan="1">p.Arg322His</td><td colspan="1" rowspan="2">No</td><td colspan="1" rowspan="2">Tolerated</td><td colspan="1" rowspan="2">Probably damaging</td><td colspan="1" rowspan="2">29.1</td><td colspan="1" rowspan="2">Novel</td><td colspan="1" rowspan="2">No</td><td colspan="1" rowspan="2">Yes</td></tr><tr><td colspan="1" rowspan="1">c.965G&gt;A</td><td colspan="1" rowspan="1">p.Arg322His</td></tr><tr><td colspan="1" rowspan="2">B8</td><td colspan="1" rowspan="2">PEX6</td><td colspan="1" rowspan="1">c.2734G&gt;A</td><td colspan="1" rowspan="1">p.Ala912Thr</td><td colspan="1" rowspan="2">No<xref ref-type="table-fn" rid="aww221-TF3"><sup>a</sup></xref></td><td colspan="1" rowspan="2">Deleterious</td><td colspan="1" rowspan="2">Probably damaging</td><td colspan="1" rowspan="2">34.0</td><td colspan="1" rowspan="2">Novel</td><td colspan="1" rowspan="2">Yes</td><td colspan="1" rowspan="2">Yes</td></tr><tr><td colspan="1" rowspan="1">c.2734G&gt;A</td><td colspan="1" rowspan="1">p.Ala912Thr</td></tr><tr><td colspan="1" rowspan="2">U1</td><td colspan="1" rowspan="2">POMGNT1</td><td colspan="1" rowspan="1">c.373C&gt;G</td><td colspan="1" rowspan="1">p.Arg125Gly</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Tolerated</td><td colspan="1" rowspan="1">Benign</td><td colspan="1" rowspan="1">21.7</td><td colspan="1" rowspan="1">Novel</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">c.1539+1G&gt;A</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">28.1</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="aww221-B43">Yoshida <italic>et al.</italic> 2001</xref></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="2">U2</td><td colspan="1" rowspan="2">DPYS</td><td colspan="1" rowspan="1">c.144_151dupGCTGCGGG</td><td colspan="1" rowspan="1">p.Val51GlyfsTer50</td><td colspan="1" rowspan="2">No</td><td colspan="1" rowspan="2">-</td><td colspan="1" rowspan="2">-</td><td colspan="1" rowspan="2">25.2</td><td colspan="1" rowspan="2"></td><td colspan="1" rowspan="2">No</td><td colspan="1" rowspan="2">Yes</td></tr><tr><td colspan="1" rowspan="1">c.144_151dupGCTGCGGG</td><td colspan="1" rowspan="1">p.Val51GlyfsTer50</td></tr><tr><td colspan="1" rowspan="2">U3</td><td colspan="1" rowspan="2">ACSF3</td><td colspan="1" rowspan="1">c.1453A&gt;C</td><td colspan="1" rowspan="1">p.Ser485Arg</td><td colspan="1" rowspan="2">Yes</td><td colspan="1" rowspan="2">Tolerated</td><td colspan="1" rowspan="2">Probably damaging</td><td colspan="1" rowspan="2">24.2</td><td colspan="1" rowspan="2">Novel</td><td colspan="1" rowspan="2">Yes</td><td colspan="1" rowspan="2">Yes</td></tr><tr><td colspan="1" rowspan="1">c.1453A&gt;C</td><td colspan="1" rowspan="1">p.Ser485Arg</td></tr><tr><td colspan="1" rowspan="2">U4</td><td colspan="1" rowspan="2">AFG3L2</td><td colspan="1" rowspan="1">c.1067T&gt;G</td><td colspan="1" rowspan="1">p.Leu356Arg</td><td colspan="1" rowspan="2">No</td><td colspan="1" rowspan="2">Deleterious</td><td colspan="1" rowspan="2">Probably damaging</td><td colspan="1" rowspan="2">29.9</td><td colspan="1" rowspan="2">Novel</td><td colspan="1" rowspan="2">Yes</td><td colspan="1" rowspan="2">Yes</td></tr><tr><td colspan="1" rowspan="1">c.1067T&gt;G</td><td colspan="1" rowspan="1">p.Leu356Arg</td></tr><tr><td colspan="1" rowspan="2">U5</td><td colspan="1" rowspan="2"><italic>SERAC1</italic></td><td colspan="1" rowspan="1">c.1850delinsCA</td><td colspan="1" rowspan="1">p.Ile617ThrfsTer6</td><td colspan="1" rowspan="2">Yes</td><td colspan="1" rowspan="2">-</td><td colspan="1" rowspan="2">-</td><td colspan="1" rowspan="2">35.0</td><td colspan="1" rowspan="2">Novel</td><td colspan="1" rowspan="2">Yes</td><td colspan="1" rowspan="2">Yes</td></tr><tr><td colspan="1" rowspan="1">c.1850delinsCA</td><td colspan="1" rowspan="1">p.Ile617ThrfsTer6</td></tr><tr><td colspan="1" rowspan="2">U6</td><td colspan="1" rowspan="2"><italic>PGAP2</italic></td><td colspan="1" rowspan="1">c.560C&gt;T</td><td colspan="1" rowspan="1">p.Ala187Val</td><td colspan="1" rowspan="2">Yes</td><td colspan="1" rowspan="2">Deleterious</td><td colspan="1" rowspan="2">Probably damaging</td><td colspan="1" rowspan="2">23.3</td><td colspan="1" rowspan="2">Novel</td><td colspan="1" rowspan="2">Yes</td><td colspan="1" rowspan="2">Yes</td></tr><tr><td colspan="1" rowspan="1">c.560C&gt;T</td><td colspan="1" rowspan="1">p.Ala187Val</td></tr><tr><td colspan="1" rowspan="4">U7</td><td colspan="1" rowspan="2"><italic>TPP1</italic></td><td colspan="1" rowspan="1">c.887G&gt;A</td><td colspan="1" rowspan="1">p.Gly296Asp</td><td colspan="1" rowspan="2">No</td><td colspan="1" rowspan="2">Deleterious</td><td colspan="1" rowspan="2">Probably damaging</td><td colspan="1" rowspan="2">24.6</td><td colspan="1" rowspan="2">Novel</td><td colspan="1" rowspan="2">Yes</td><td colspan="1" rowspan="2">No</td></tr><tr><td colspan="1" rowspan="1">c.887G&gt;A</td><td colspan="1" rowspan="1">p.Gly296Asp</td></tr><tr><td colspan="1" rowspan="2"><italic>ALDOB</italic></td><td colspan="1" rowspan="1">c.178C&gt;T</td><td colspan="1" rowspan="1">p.Arg60Ter</td><td colspan="1" rowspan="2">No<sup>b</sup></td><td colspan="1" rowspan="2">-</td><td colspan="1" rowspan="2">-</td><td colspan="1" rowspan="2">37.0</td><td colspan="1" rowspan="2"><xref ref-type="bibr" rid="aww221-B27">Santer <italic>et al.</italic>, 2005</xref></td><td colspan="1" rowspan="2"></td><td colspan="1" rowspan="2">Yes</td></tr><tr><td colspan="1" rowspan="1">c.178C&gt;T</td><td colspan="1" rowspan="1">p.Arg60Ter</td></tr><tr><td colspan="1" rowspan="2">U8</td><td colspan="1" rowspan="2"><italic>GALE</italic></td><td colspan="1" rowspan="1">c.280G&gt;A</td><td colspan="1" rowspan="1">p.Val94Met</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Deleterious</td><td colspan="1" rowspan="1">Possibly damaging</td><td colspan="1" rowspan="1">29.9</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="aww221-B39">Wohlers <italic>et al.</italic>, 1999</xref></td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">c.284G&gt;A</td><td colspan="1" rowspan="1">p.Gly95Asp</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Deleterious</td><td colspan="1" rowspan="1">Probably damaging</td><td colspan="1" rowspan="1">33.0</td><td colspan="1" rowspan="1">Novel</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="aww221-TF3"><p>The maximum minor allele frequency (MAF) for any variant considered to be potentially pathogenic was 0.5%.</p></fn><fn id="aww221-TF4"><p><sup>a</sup>Parental DNA was unavailable but Sanger sequencing identified the same homozygous mutation in a similarly affected sister.</p></fn><fn id="aww221-TF5"><p><sup>b</sup>Parental DNA was unavailable but Sanger sequencing identified the same homozygous mutation in a brother who also had an abnormal type I transferrin isoelectric focusing pattern.</p></fn><fn id="aww221-TF6"><p><sup>c</sup>Second mutation not identified. CADD = Combined Annotation Dependent Depletion.</p></fn></table-wrap-foot></table-wrap><table-wrap id="aww221-T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Patients with no diagnosis identified though the genetic panel</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th colspan="1" rowspan="1">ID</th><th colspan="1" rowspan="1">Gender</th><th colspan="1" rowspan="1">Age (years)</th><th colspan="1" rowspan="1">Primary neurological phenotype</th><th colspan="1" rowspan="1">Other phenotypic features</th><th colspan="1" rowspan="1">Relevant specialist investigations</th><th colspan="1" rowspan="1">MRI head</th><th colspan="1" rowspan="1">Eventual diagnosis</th></tr></thead><tbody align="left"><tr><td align="left" colspan="1" rowspan="1">B9</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Developmental delay, absence seizures</td><td align="left" colspan="1" rowspan="1">Bilateral sensorineural deafness</td><td align="left" colspan="1" rowspan="1">Grossly elevated plasma proline. Elevated n-pyrrole-2-carboxyglycine confirming hyperprolinaemia type II</td><td align="left" colspan="1" rowspan="1">Not performed</td><td align="left" colspan="1" rowspan="1">Hyperprolinaemia type II (novel homozygous deletion in <italic>ALDH4A1</italic>)</td></tr><tr><td align="left" colspan="1" rowspan="1">U9</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Learning difficulties. Delayed motor milestones, reduced exercise tolerance, responsive to intra-muscular vitamin B12 injections</td><td align="left" colspan="1" rowspan="1">Joint hypermobility</td><td align="left" colspan="1" rowspan="1">Methylmalonic aciduria and high plasma homocysteine, muscle biopsy normal</td><td align="left" colspan="1" rowspan="1">Normal</td><td align="left" colspan="1" rowspan="1">Not yet reached</td></tr><tr><td align="left" colspan="1" rowspan="1">U10</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Global developmental delay, neurological regression, dys phagia, epilepsy</td><td align="left" colspan="1" rowspan="1">Alopecia, reflux, neutropenia, platelet dysfunction</td><td align="left" colspan="1" rowspan="1">Intermittently elevated plasma lactate but normal CSF lactate, low plasma manganese</td><td align="left" colspan="1" rowspan="1">Leigh-like changes in the basal ganglia and brainstem</td><td align="left" colspan="1" rowspan="1">Not yet reached</td></tr><tr><td align="left" colspan="1" rowspan="1">U11</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Episodes of severe ketotic hypoglycaemia with seizures</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">Normal acylcarnitines, plasma amino acids. Slightly low fructose-1,6-bisphosphatase activity</td><td align="left" colspan="1" rowspan="1">Not performed</td><td align="left" colspan="1" rowspan="1">Not yet reached</td></tr><tr><td align="left" colspan="1" rowspan="1">U12</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Developmental delay and regression, dysphagia</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">Low vitamin B12</td><td align="left" colspan="1" rowspan="1">Delayed myelination</td><td align="left" colspan="1" rowspan="1">Multiple mutations, only one of which picked up by gene panel <italic>CUBN</italic> (p.Ala2194Val)</td></tr><tr><td align="left" colspan="1" rowspan="1">U13</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">One of similarly affected siblings. Parental consanguinity. Developmental delay, reduced exercise tolerance, joint hypermobility</td><td align="left" colspan="1" rowspan="1">Dysmorphic features. Pancreatic insufficiency and fat malabsorption</td><td align="left" colspan="1" rowspan="1">Several raised plasma amino acids. Muscle histology suggestive of mitochondrial disorder but RCE normal</td><td align="left" colspan="1" rowspan="1">Normal</td><td align="left" colspan="1" rowspan="1">Not yet reached</td></tr><tr><td align="left" colspan="1" rowspan="1">U14</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">One of similarly affected siblings. Parental consanguinity. Developmental delay, reduced exercise tolerance, joint hypermobility</td><td align="left" colspan="1" rowspan="1">Pancreatic insufficiency and fat malabsorption.</td><td align="left" colspan="1" rowspan="1">Several raised plasma amino acids.</td><td align="left" colspan="1" rowspan="1">Not performed</td><td align="left" colspan="1" rowspan="1">Not yet reached</td></tr><tr><td align="left" colspan="1" rowspan="1">U15</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Global delay, microcephaly. Movement disorder with chorea and non-epileptic myoclonic jerks</td><td align="left" colspan="1" rowspan="1">Previous faltering growth. Renal tubular acidosis on NaHCO<sub>3</sub> supplements</td><td align="left" colspan="1" rowspan="1">No other abnormalities</td><td align="left" colspan="1" rowspan="1">Delayed myelination</td><td align="left" colspan="1" rowspan="1">Not yet reached</td></tr><tr><td align="left" colspan="1" rowspan="1">U16</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">Global delay, seizures, dysphagia. Sibling with similar features</td><td align="left" colspan="1" rowspan="1">Dysmorphism</td><td align="left" colspan="1" rowspan="1">Persistent low arginine but normal lactate, carnitine profile and urine organic acids</td><td align="left" colspan="1" rowspan="1">Leukodystrophy</td><td align="left" colspan="1" rowspan="1">Unconfirmed <italic>NDUFS1</italic> deletions</td></tr><tr><td align="left" colspan="1" rowspan="1">U17</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Global delay, retinal dystrophy, dystonic extensor spasms, epilepsy</td><td align="left" colspan="1" rowspan="1">Reflux, hip dislocation, scoliosis</td><td align="left" colspan="1" rowspan="1">EEG features consistent with Electrical Status Epilepticus in Sleep (ESES)</td><td align="left" colspan="1" rowspan="1">Progressive cerebral and cerebellar atrophy</td><td align="left" colspan="1" rowspan="1">Microarray: deletion at 7q36.2 - <italic>de novo</italic> change which includes <italic>DPP6</italic> gene, known to be associated with neurological disorders. DDD ongoing</td></tr><tr><td align="left" colspan="1" rowspan="1">U18</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">Developmental delay, paroxysmal episodes of gasping, opisthotonus and discomfort related to food ingestion</td><td align="left" colspan="1" rowspan="1">Distinct facial features. Abnormal maculae on OCT and slightly swollen optic discs</td><td align="left" colspan="1" rowspan="1">Abnormal visual evoked potential (VEP)/electroretinogram (ERG)</td><td align="left" colspan="1" rowspan="1">Non-progressive ventricular dilatation</td><td align="left" colspan="1" rowspan="1"><italic>KANSL1</italic> c.1635-3T&gt;C; Koolen-de Vries syndrome. Diagnosis made by geneticists</td></tr><tr><td align="left" colspan="1" rowspan="1">U19</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Global delay. 4-limb motor disorder with variable increased tone. Xp21 in-frame deletion within dystrophin gene</td><td align="left" colspan="1" rowspan="1">Sister with similar phenotype but without the dystrophin deletion</td><td align="left" colspan="1" rowspan="1">High CK. Very long chain fatty acids: moderately raised C26 and C26:C22 ratio.</td><td align="left" colspan="1" rowspan="1">Normal</td><td align="left" colspan="1" rowspan="1">Not yet reached</td></tr><tr><td align="left" colspan="1" rowspan="1">U20</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Faltering growth, poor feeding, hypoglycaemia and lethargy at 5 months. Marked hypotonia and hyper-reflexia at presentation</td><td align="left" colspan="1" rowspan="1">Rapid evolution to multiorgan failure- passed away shortly afterwards</td><td align="left" colspan="1" rowspan="1">Lactic acidosis, persistent. NH<sub>3</sub> 88 µmol/L. Mitochondrial genome analysis normal, <italic>POLG</italic> common mutations normal</td><td align="left" colspan="1" rowspan="1">Agenesis of corpus callosum and colpocephaly</td><td align="left" colspan="1" rowspan="1"><italic>EARS2</italic> variant picked up by the panel. Functional work underway to establish its significance.</td></tr><tr><td align="left" colspan="1" rowspan="1">U21</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Global delay, acquired microcephaly</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">Persistently low levels of branched-chain amino acids in plasma and CSF</td><td align="left" colspan="1" rowspan="1">Lack of white matter bulk and delayed myelination</td><td align="left" colspan="1" rowspan="1"><italic>BCKDK</italic> mutations – gene not on panel. Diagnosis by targeted gene testing</td></tr></tbody></table><table-wrap-foot><fn id="aww221-TF2"><p>After gene panel analysis, some of the patients in our cohort had diagnoses established via comparative genomic hybridization array or targeted genetic testing. Patient U29 had <italic>EARS2</italic> mutations identified through the panel which would be consistent with the clinical phenotype. However, as the same variants were also encountered in unrelated non-affected individuals, their significance is still being investigated through functional studies (data not shown). Patient U25 had <italic>NDUFS1</italic> deletions identified through our panel; however, these were not confirmed via Sanger sequencing. CK = creatine kinase; OCT = ocular computerized tomography; RCE = respiratory chain enzymes.</p></fn></table-wrap-foot></table-wrap></p>
</sec>
<sec>
<title>Gene capture, sequencing and variant analysis</title>
<p>A custom HaloPlex target enrichment system (Agilent) was used to capture 614 genes, covering 16 broad classes of IEM (<xref ref-type="supplementary-material" rid="sup1">Supplementary material</xref>). Sequencing was performed using the HiSeq 2500 platform (Illumina). Sequence variants with putatively deleterious effects were confirmed by Sanger sequencing (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 4</xref>). To interrogate for potential pathogenicity in identified variants, we investigated whether variants had been reported previously as pathogenic, their frequency in the population, segregation within the family (where samples were available) and predicted functional impact utilizing SIFT (<ext-link ext-link-type="uri" xlink:href="http://sift.bii.a-star.edu.sg/">http://sift.bii.a-star.edu.sg/</ext-link>), PolyPhen-2 (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</ext-link>) and Combined Annotation Dependent Depletion (CADD) (<ext-link ext-link-type="uri" xlink:href="http://cadd.gs.washington.edu/">http://cadd.gs.washington.edu/</ext-link>). Where possible, missense variants were mapped to known 3D protein structures and compared to <italic>in silico</italic> findings (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 5</xref>).</p>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Panel validation</title>
<p>Nineteen of 20 pathogenic sequence variants were identified in the 13 genetically diagnosed control samples (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1</xref>). These included seven heterozygous and five homozygous missense, two heterozygous splice site mutations, a heterozygous single base insertion and four deletions ranging in size from 2 bp to ∼6 kbp. The homozygous 37-amino acid deletion in Patient D6 was not identified. Seven of 20 variants had not been previously reported in the literature.</p>
</sec>
<sec>
<title>Clinical characteristics of undiagnosed cohort</title>
<p>Age ranged from 1 to 20 years (mean 7.2 years, median 6 years). Only 9/30 patients (Patients B1–B9, <xref ref-type="table" rid="aww221-T1 aww221-T2 aww221-T3">Tables 1–3</xref>) had abnormal biochemistry suggestive of an underlying genetic diagnosis, despite previous extensive testing in all cases. Our panel identified 21 variants in 16 patients, of which only seven had previously been reported in the literature (<xref ref-type="bibr" rid="aww221-B24">Reichardt <italic>et al.</italic>, 1991; 1992</xref>; <xref ref-type="bibr" rid="aww221-B30">Shen <italic>et al.</italic>, 1996</xref>; <xref ref-type="bibr" rid="aww221-B39">Wohlers <italic>et al.</italic>, 1999</xref>; <xref ref-type="bibr" rid="aww221-B2">Aoshima <italic>et al.</italic>, 2001</xref>; <xref ref-type="bibr" rid="aww221-B43">Yoshida <italic>et al.</italic>, 2001</xref>; <xref ref-type="bibr" rid="aww221-B27">Santer <italic>et al.</italic>, 2005</xref>). Ten variants were classified as pathogenic, 10 as likely pathogenic and one of uncertain significance (<xref ref-type="bibr" rid="aww221-B25">Richards <italic>et al.</italic>, 2015</xref>) (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 5</xref>). Variants included 15 missense, two nonsense, three insertions/deletions and one splice site mutation. Identified variants could at least partially explain the observed clinical phenotype in all cases.</p>
<p>Of nine patients with previous biochemical testing pointing towards a diagnosis, identification of pathogenic variants was possible for eight (88.8%). Parental DNA to check segregation within families was not available. We were unable to identify any potential pathogenic variants in Patient B9, whose biochemical profile suggested hyperprolinaemia type II and, in whom, a homozygous complex insertion/deletion event resulting in a frameshift and premature stop codon in <italic>ALDH4A1</italic> was subsequently identified via Sanger sequencing. Otherwise, in most other cases, two pathogenic variants were identified in each candidate gene.</p>
<p>We were also able to attain a molecular genetic diagnosis in 8/21 (38%) of patients without a biochemical marker pointing towards a specific genetic diagnosis (<xref ref-type="table" rid="aww221-T1 aww221-T2 aww221-T3">Tables 1–3</xref>). Two pathogenic (or likely pathogenic) variants were identified for each candidate gene. All variants were confirmed by Sanger sequencing in probands and family members where possible. Detailed clinical descriptions of these patients are given in the <xref ref-type="supplementary-material" rid="sup1">Supplementary material</xref>. In Patients B6, B7 and U2, the identified variants could explain the biochemical abnormalities but not other clinical features observed, indicating the presence of other, as yet unidentified gene defects. Additionally, Patient U7 had pathogenic variants identified in <italic>ALDOB</italic> and <italic>TPP1</italic>, while the clinical and biochemical phenotype was consistent with simultaneous presence of mutations in both genes (<xref ref-type="supplementary-material" rid="sup1">Supplementary material</xref>).</p>
</sec>
<sec id="SEC3D">
<title>3D structure analysis</title>
<p>3D structural analysis of identified variants was performed using the ICM-Pro software (Molsoft LLC), when structural data were available for the proteins (Patients B2, U7 and U8) or for ‘close homologues/orthologues’ (Patients B8 and U4) (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 6</xref>). The impact of the amino acid substitution for six missense variants, all predicted to be deleterious and probably/possibly damaging by SIFT and PolyPhen-2, was determined by mapping them onto the wild-type structures and inspecting potential changes in bonding interactions, packing and secondary structures due to the amino acid substitution. In all cases, our structure-guided findings concurred with <italic>in silico</italic> prediction software, further supporting variant pathogenicity.</p>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In our study, we investigated the utility of an extended gene panel in diagnosing patients with neurometabolic disorders. Due to the marked clinical, biochemical and genetic heterogeneity encountered in neurometabolic disease, targeted gene testing is often not advantageous, economical or efficient. The panel described in our study was shown to be a powerful tool that enhances the diagnostic ability in the clinical setting. It covers 614 genes, including the vast majority of genes currently known to cause neurometabolic disease, hence sharing similarities with WES approaches but with the added advantage of more optimal coverage of targeted areas (<xref ref-type="bibr" rid="aww221-B14">Kammermeier <italic>et al.</italic>, 2014</xref>). Indeed, coverage of targeted areas was similar or superior to that reported in other gene panels despite the large number of genes covered (<xref ref-type="bibr" rid="aww221-B21">Nemeth <italic>et al.</italic>, 2013</xref>; <xref ref-type="bibr" rid="aww221-B42">Yohe <italic>et al.</italic>, 2015</xref>). Moreover, the diagnosis rate in our study was comparable to, or higher than, that reported in similar approaches recently applied in other patient groups exhibiting phenotypic heterogeneity (<xref ref-type="bibr" rid="aww221-B14">Kammermeier <italic>et al.</italic>, 2014</xref>; <xref ref-type="bibr" rid="aww221-B32">Sommen <italic>et al.</italic>, 2016</xref>; <xref ref-type="bibr" rid="aww221-B34">Trump <italic>et al.</italic>, 2016</xref>).</p>
<p>We investigated patients with a wide array of, and often non-specific, neurometabolic symptomatology and were able to identify disease-causing mutations in a large number of cases. We interrogated 30 cases with no definitive molecular diagnosis despite having had all the pathology laboratory (including metabolic biochemistry) tests and imaging modalities that a tertiary referral metabolic centre considered might lead to a diagnosis. Of the 21/30 patients lacking pointers towards an underlying molecular diagnosis, pathogenic variants that explained all the clinical and biochemical findings were identified in seven (33%) and some of the phenotypic features in one (5%); demonstrating the effectiveness of this approach in a clinically heterogeneous, diagnostically challenging cohort. In these patients, there was no clear phenotypic or biochemical feature associated with higher or lower diagnostic rates on our panel, although study numbers preclude further conclusions. Additionally, where suggestive biochemical abnormalities existed, our panel efficiently led to a definitive genetic diagnosis in 8/9 cases. However, it is important to note that our cohort was recruited through a single tertiary referral centre, which may lead to selection bias. Therefore, further studies using large cohorts of patients consecutively enrolled from multiple metabolic medicine centres are warranted to establish the exact sensitivity and specificity of our panel. Nevertheless, we demonstrate that our extended panel approach, with subsequent focus on candidate gene(s), can be an initial relatively cost-effective approach to investigate patients with suspected neurometabolic disorders. Moreover, although applied to a paediatric cohort, our approach would arguably be even more useful in adult populations, where neurometabolic phenotypes can be even more atypical, presentations more variable and biochemical phenotypes even more subtle. Indeed, many lysosomal storage, mitochondrial, peroxisomal and other metabolic disorders present atypically in adults. For example, adrenoleukodystrophy can present as early-onset dementia (<xref ref-type="bibr" rid="aww221-B16">Kumar <italic>et al.</italic>, 1995</xref>). Patients with urea cycle disorders, organic acidaemias and Niemann Pick type C can also exhibit psychiatric manifestations (<xref ref-type="bibr" rid="aww221-B29">Sedel <italic>et al.</italic>, 2007</xref>). Thus, a comprehensive panel approach can have high utility in patients presenting with unexplained/atypical psychiatric or neurological manifestations.</p>
<p>Our study expands the genotypic and phenotypic spectrum of several disorders but also re-emphasizes the complexity of diagnosing patients with IEM. Patient U1 presented with a multi-system disorder and significant myopathy; however, due to unremarkable brain imaging and a non-diagnostic muscle biopsy (<xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. 1</xref>), the diagnosis of <italic>POMGNT1</italic>-related dystroglycanopathy was delayed. Although uncommon, normal glycosylated α-dystroglycan immunofluorescence staining has been reported previously in <italic>POMGNT1</italic> patients (<xref ref-type="bibr" rid="aww221-B6">Clement <italic>et al.</italic>, 2008</xref>). Patient U7 had neurodevelopmental difficulties and hyper-reflexia, hence representing a mild <italic>TPP1</italic>-related phenotype compared to those typically reported in the literature (<xref ref-type="bibr" rid="aww221-B4">Breedveld <italic>et al.</italic>, 2004</xref>; <xref ref-type="bibr" rid="aww221-B33">Sun <italic>et al.</italic>, 2013</xref>), whereas his abnormal transferrin isoelectric focusing was attributable to the <italic>ALDOB</italic> mutations. Indeed, following variant identification, tripeptidyl peptidase I activity in patient leucocytes was found to be at the upper boundary of the affected range. The above cases demonstrate the spectrum of severity associated with IEM and how common it is for clinicians investigating neurometabolic disorders to be misguided by investigation results, with resulting diagnostic delays. For example, an abnormal transferrin pattern combined with neurological dysfunction would prompt investigations for congenital disorders of glycosylation (<xref ref-type="bibr" rid="aww221-B28">Scott <italic>et al.</italic>, 2014</xref>), which was the case in Patient U8 in whom variants in <italic>GALE</italic> were identified and UDP-galactose 4’-epimerase activity was subsequently found to be undetectable.</p>
<p>Apart from expanding the phenotypic spectrum of ‘well-described’ disorders, our results help expand the genotypic and phenotypic spectrum of recently described genetic conditions including <italic>PGAP2</italic> (<xref ref-type="bibr" rid="aww221-B11">Hansen <italic>et al.</italic>, 2013</xref>; <xref ref-type="bibr" rid="aww221-B15">Krawitz <italic>et al.</italic>, 2013</xref>), <italic>ACSF3</italic> (<xref ref-type="bibr" rid="aww221-B31">Sloan <italic>et al.</italic>, 2011</xref>), <italic>DPYS</italic> (<xref ref-type="bibr" rid="aww221-B36">van Kuilenburg <italic>et al.</italic>, 2010</xref>), <italic>AFG3L2</italic> (<xref ref-type="bibr" rid="aww221-B22">Pierson <italic>et al.</italic>, 2011</xref>) and <italic>SERAC1</italic> (<xref ref-type="bibr" rid="aww221-B40">Wortmann <italic>et al.</italic>, 2012</xref>). Hence, panel approaches enable clinicians to establish diagnoses in (and increase awareness of) ever broadening phenotypes and recently-described disorders, while at the same time circumventing problematic heterogeneity issues and potentially shortening the time to establish a definitive diagnosis for some patients.</p>
<p>Some patients with IEM have defects in more than one gene contributing to observed phenotypes. Patient U7 had mutations in <italic>ALDOB</italic> and <italic>TPP1</italic>. While mutations in <italic>ALDOB</italic> have been associated with abnormal transferrin patterns (<xref ref-type="bibr" rid="aww221-B1">Adamowicz <italic>et al.</italic>, 2007</xref>), the majority of clinical features seen in this case are likely attributable to the <italic>TPP1</italic> mutation (<xref ref-type="bibr" rid="aww221-B4">Breedveld <italic>et al.</italic>, 2004</xref>; <xref ref-type="bibr" rid="aww221-B33">Sun <italic>et al.</italic>, 2013</xref>). Similarly, Patients B6 and B7 had mutations in <italic>AASS</italic>, which would explain the hyperlysinaemia seen in both plasma and CSF but not the presence of developmental delay, microcephaly, hypotonia and epilepsy (<xref ref-type="bibr" rid="aww221-B12">Houten <italic>et al.</italic>, 2013</xref>). Patient U2 had mutations in <italic>DPYS</italic>, which are associated with abnormal purine and pyrimidine metabolites but not with dysplastic kidneys, eczema, microcephaly and developmental delay (<xref ref-type="bibr" rid="aww221-B36">van Kuilenburg <italic>et al.</italic>, 2010</xref>). The phenotypic features in these patients are most likely attributable to other, yet unidentified, genetic defects. The existence of pathogenic variants at two genetic loci in one patient is not surprising, as individuals have ∼3.5 million variants in their genome (<xref ref-type="bibr" rid="aww221-B9">Gonzaga-Jauregui <italic>et al.</italic>, 2012</xref>). A recent genetic study showed that 4.6% of participants had blended phenotypes resulting from two single gene defects (<xref ref-type="bibr" rid="aww221-B41">Yang <italic>et al.</italic>, 2014</xref>). The above issues further complicate the diagnosis of IEM and highlight the utility of NGS, especially in highly heterogeneous disorders while emphasizing the need for diagnosticians to perform elaborate clinical phenotyping and not over-rely on sequencing results, especially when identified gene defects do not account fully for the observed clinical picture.</p>
<p>Despite our panel’s usefulness, there were also limitations in our approach. No potential disease-causing gene alterations were identified in 14/30 patients. While established metrics indicate that our capture efficiency and depth of coverage was good overall (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 3</xref>), mutations may have been missed because of less efficient capture of GC-rich regions or low coverage due to sample complexity. It is also plausible that the disease-causing genes were not included in our design or that the causative mutations were intronic or within regulatory regions. We were also unable to identify the second pathogenic variant in Patient B3 (CPS1 deficiency), possibly because it lies within exon 21 (regions of which were only covered at a read depth of 3×), an intronic area or a promoter region. More research including WES or WGS in mutation-negative cases is warranted to reach further conclusions. Overall, our findings agree with previous studies indicating that, when analysed by NGS, targeted genetic regions can be inconsistently covered at read depths sufficient for comprehensive variant analysis (<xref ref-type="bibr" rid="aww221-B7">Dewey <italic>et al.</italic>, 2014</xref>). Additionally, although able to identify deletions, we were unable to detect the homozygous 111 bp deletion in Patient D6 or insertion/deletion event in Patient B9, which highlights the challenges of using NGS to detect copy number variants (<xref ref-type="bibr" rid="aww221-B20">Mullaney <italic>et al.</italic>, 2010</xref>). Indeed, some common pathogenic alleles can be missed by conventional sequencing approaches, including targeted NGS, unless methods are specifically adapted or additional assays are included to capture them. These can include deep intronic splice variants as in leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (<xref ref-type="bibr" rid="aww221-B35">van Berge <italic>et al.</italic>, 2014</xref>) or whole gene deletions and duplications as in Pelizaeus-Merzbacher disease (<xref ref-type="bibr" rid="aww221-B17">Lee <italic>et al.</italic>, 2006</xref>).</p>
<p>Finally, detection of variants of uncertain significance could pose a diagnostic and ethical issue, especially in patients with specific phenotypes where more targeted genetic testing could be a reasonable alternative. We firstly addressed this by following a ‘panel within a panel’ approach, initially interrogating genes in which mutations were likely to result in the observed phenotypes (e.g. <italic>MUT</italic>, <italic>MCEE</italic>, <italic>ACSF3</italic>, <italic>ALDH6A1</italic>, <italic>MMAA</italic>, <italic>MMAB</italic>, <italic>SUCLA2</italic>, <italic>LMBRD1</italic>, <italic>ABCD4</italic>, <italic>MMADHC</italic> and <italic>MMACHC</italic> in patients with methylmalonic aciduria) and expanding our search when no likely pathogenic variants were identified. Moreover, during the consenting process, we specifically counselled all study participants that they would not be informed about variants that were not deemed relevant to the clinical presentation. Utilizing expert phenotyping, current guidance on variant interpretation (<xref ref-type="bibr" rid="aww221-B25">Richards <italic>et al.</italic>, 2015</xref>) and close collaboration between clinicians and scientists interrogating the data is crucial for the above to be successfully implemented. Nevertheless, our study shows that such approaches are feasible, even in patients with more specific clinical and/or biochemical phenotypes. This approach is particularly applicable in various neurometabolic conditions (such as the cases of peroxisomal biogenesis disorders and congenital disorders of glycosylation in our cohort), where mutations in a large number of genes could lead to similar biochemical abnormalities.</p>
<p>We also encountered difficulties when utilizing <italic>in silico</italic> tools for novel missense variant interpretation. When using SIFT and PolyPhen-2 interpretation, discordance was occasionally evident, not only for novel variants but also for common variants of established pathogenicity in <italic>ASL</italic> (<xref ref-type="bibr" rid="aww221-B18">Linnebank <italic>et al.</italic>, 2002</xref>) and <italic>GALT</italic> (<xref ref-type="bibr" rid="aww221-B23">Reichardt <italic>et al.</italic>, 1992</xref>) (<xref ref-type="table" rid="aww221-T1">Tables 2</xref> and <xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1</xref>). However, despite this discordance, CADD scores for these variants rank them more deleterious than 99.5% of all possible human single nucleotide variants. Additionally, SIFT, PolyPhen-2 and CADD suggested that a known pathogenic <italic>IDUA</italic> variant (<xref ref-type="bibr" rid="aww221-B3">Bach <italic>et al.</italic>, 1993</xref>) was not likely to be deleterious (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1</xref>). Inability of online prediction tools, particularly those using sequence-based algorithms, to predict pathogenicity of all variants analysed correctly has been evaluated previously (<xref ref-type="bibr" rid="aww221-B5">Castellana and Mazza, 2013</xref>; <xref ref-type="bibr" rid="aww221-B8">Dong <italic>et al.</italic>, 2015</xref>; <xref ref-type="bibr" rid="aww221-B38">Walters-Sen <italic>et al.</italic>, 2015</xref>). <italic>In silico</italic> tools remain invaluable in filtering large numbers of variants identified using NGS platforms; however, further evidence to support or refute pathogenicity should be sought (<xref ref-type="bibr" rid="aww221-B25">Richards <italic>et al.</italic>, 2015</xref>), for example segregation analysis and enzymatic assays in appropriate patient tissues. In our study, we further characterized identified missense variants by mapping them to 3D protein structures where possible. All variants were predicted to be deleterious and probably/possibly damaging by SIFT and PolyPhen-2 and structural analysis supported these predictions in all cases, providing further evidence of pathogenicity. Should 3D structural information become available for larger parts of the human exome, this approach could become a valuable aid towards novel variant analysis (<xref ref-type="bibr" rid="aww221-B44">Yue <italic>et al.</italic>, 2014</xref>).</p>
<p>Extended panel approaches have gained popularity and are used by many clinical laboratories in the investigation of a wide range of genetically heterogeneous conditions (<ext-link ext-link-type="uri" xlink:href="http://www.labs.gosh.nhs.uk/media/759058/goshome_v7.pdf">http://www.labs.gosh.nhs.uk/media/759058/goshome_v7.pdf</ext-link>) including neurometabolic disease. With decreasing NGS costs and the advent of the Genomics England 100 000 Genomes Project, WES and WGS will likely supersede the use of gene panels in the clinical diagnostic setting in the future. However, many challenges remain prior to this implementation, including difficulties in interpreting overwhelming amounts of data generated and uncertainties about clinically reportable findings (<xref ref-type="bibr" rid="aww221-B7">Dewey <italic>et al.</italic>, 2014</xref>). Moreover, WES and WGS have proven invaluable in the identification of novel genes (<xref ref-type="bibr" rid="aww221-B26">Saitsu <italic>et al.</italic>, 2013</xref>; <xref ref-type="bibr" rid="aww221-B13">Howard <italic>et al.</italic>, 2014</xref>) but such findings are not currently actionable within the diagnostic setting. Elucidating the significance of these variants is not possible without functional characterization in appropriate settings and models, which is often expensive and beyond the capacity of most clinical diagnostic laboratories. Until such challenges are surpassed, gene panel approaches provide a rapid and cost-effective method of testing patients with neurometabolic disorders and enable more timely diagnosis and prompt treatment initiation in these conditions.</p>
</sec>
<sec>
<title>Funding</title>
<p>P.B.M. and P.T.C. received Great Ormond Street Hospital Children’s Charity (GOSHCC) Leadership awards (V2516 and V1254). P.G. is a Wellcome Trust Senior Research fellow. S.R. is supported by Great Ormond Street Hospital Children's Charity (GOSHCC) Research Leadership Grant V1260. A.P. holds a joint Action Medical Research (AMR) and British Paediatric Neurology Association (BPNA) fellowship. This project was funded by grants from the University College London Impact Award and GOSHCC Metabolic Fund and supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary material</title>
<p>
Supplementary material is available <xref ref-type="supplementary-material" rid="sup1">here</xref>.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="sup1">
<label>Supplementary Data</label>
<media xlink:href="aww221_supplementary_data.zip">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item>
<term id="G1">IEM</term>
<def>
<p>inborn errors of metabolism</p>
</def>
</def-item>
<def-item>
<term id="G2">NGS</term>
<def>
<p>next-generation sequencing</p>
</def>
</def-item>
<def-item>
<term id="G3">WES</term>
<def>
<p>whole-exome sequencing</p>
</def>
</def-item>
<def-item>
<term id="G4">WGS</term>
<def>
<p>whole-genome sequencing</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="aww221-B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Adamowicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Ploski</surname><given-names>R</given-names></name><name name-style="western"><surname>Rokicki</surname><given-names>D</given-names></name><name name-style="western"><surname>Morava</surname><given-names>E</given-names></name><name name-style="western"><surname>Gizewska</surname><given-names>M</given-names></name><name name-style="western"><surname>Mierzewska</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Transferrin hypoglycosylation in hereditary fructose intolerance: using the clues and avoiding the pitfalls</article-title>. <source/>J Inherit Metab Dis<year>2007</year>; <volume>30</volume>: <fpage>407</fpage>.<pub-id pub-id-type="pmid">17457694</pub-id></mixed-citation>
</ref>
<ref id="aww221-B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Aoshima</surname><given-names>T</given-names></name><name name-style="western"><surname>Kajita</surname><given-names>M</given-names></name><name name-style="western"><surname>Sekido</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>I</given-names></name><name name-style="western"><surname>Saheki</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Novel mutations (H337R and 238-362del) in the CPS1 gene cause carbamoyl phosphate synthetase I deficiency</article-title>. <source/>Hum Hered<year>2001</year>; <volume>52</volume>: <fpage>99</fpage>–<lpage>101</lpage>.<pub-id pub-id-type="pmid">11474210</pub-id></mixed-citation>
</ref>
<ref id="aww221-B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bach</surname><given-names>G</given-names></name><name name-style="western"><surname>Moskowitz</surname><given-names>SM</given-names></name><name name-style="western"><surname>Tieu</surname><given-names>PT</given-names></name><name name-style="western"><surname>Matynia</surname><given-names>A</given-names></name><name name-style="western"><surname>Neufeld</surname><given-names>EF</given-names></name></person-group>
<article-title>Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area</article-title>. <source/>Am J Hum Genet<year>1993</year>; <volume>53</volume>: <fpage>330</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">8328452</pub-id></mixed-citation>
</ref>
<ref id="aww221-B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Breedveld</surname><given-names>GJ</given-names></name><name name-style="western"><surname>van Wetten</surname><given-names>B</given-names></name><name name-style="western"><surname>te Raa</surname><given-names>GD</given-names></name><name name-style="western"><surname>Brusse</surname><given-names>E</given-names></name><name name-style="western"><surname>van Swieten</surname><given-names>JC</given-names></name><name name-style="western"><surname>Oostra</surname><given-names>BA</given-names></name><etal></etal></person-group>
<article-title>A new locus for a childhood onset, slowly progressive autosomal recessive spinocerebellar ataxia maps to chromosome 11p15</article-title>. <source/>J Med Genet<year>2004</year>; <volume>41</volume>: <fpage>858</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">15520412</pub-id></mixed-citation>
</ref>
<ref id="aww221-B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Castellana</surname><given-names>S</given-names></name><name name-style="western"><surname>Mazza</surname><given-names>T</given-names></name></person-group>
<article-title>Congruency in the prediction of pathogenic missense mutations: state-of-the-art web-based tools</article-title>. <source/>Brief Bioinform<year>2013</year>; <volume>14</volume>: <fpage>448</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">23505257</pub-id></mixed-citation>
</ref>
<ref id="aww221-B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Clement</surname><given-names>EM</given-names></name><name name-style="western"><surname>Godfrey</surname><given-names>C</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name><name name-style="western"><surname>Brockington</surname><given-names>M</given-names></name><name name-style="western"><surname>Torelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant</article-title>. <source/>Arch Neurol<year>2008</year>; <volume>65</volume>: <fpage>137</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">18195152</pub-id></mixed-citation>
</ref>
<ref id="aww221-B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dewey</surname><given-names>FE</given-names></name><name name-style="western"><surname>Grove</surname><given-names>ME</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>BA</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chaib</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Clinical interpretation and implications of whole-genome sequencing</article-title>. <source/>JAMA<year>2014</year>; <volume>311</volume>: <fpage>1035</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">24618965</pub-id></mixed-citation>
</ref>
<ref id="aww221-B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>C</given-names></name><name name-style="western"><surname>Wei</surname><given-names>P</given-names></name><name name-style="western"><surname>Jian</surname><given-names>X</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>R</given-names></name><name name-style="western"><surname>Boerwinkle</surname><given-names>E</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies</article-title>. <source/>Hum Mol Genet<year>2015</year>; <volume>24</volume>: <fpage>2125</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">25552646</pub-id></mixed-citation>
</ref>
<ref id="aww221-B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gonzaga-Jauregui</surname><given-names>C</given-names></name><name name-style="western"><surname>Lupski</surname><given-names>JR</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>RA</given-names></name></person-group>
<article-title>Human genome sequencing in health and disease</article-title>. <source/>Annu Rev Med<year>2012</year>; <volume>63</volume>: <fpage>35</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">22248320</pub-id></mixed-citation>
</ref>
<ref id="aww221-B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>L</given-names></name><name name-style="western"><surname>Tawamie</surname><given-names>H</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mang</surname><given-names>Y</given-names></name><name name-style="western"><surname>ur Rehman</surname><given-names>S</given-names></name><name name-style="western"><surname>Buchert</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Hypomorphic mutations in PGAP2, encoding a GPI-anchor-remodeling protein, cause autosomal-recessive intellectual disability</article-title>. <source/>Am J Hum Genet<year>2013</year>; <volume>92</volume>: <fpage>575</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">23561846</pub-id></mixed-citation>
</ref>
<ref id="aww221-B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Houten</surname><given-names>SM</given-names></name><name name-style="western"><surname>Te Brinke</surname><given-names>H</given-names></name><name name-style="western"><surname>Denis</surname><given-names>S</given-names></name><name name-style="western"><surname>Ruiter</surname><given-names>JP</given-names></name><name name-style="western"><surname>Knegt</surname><given-names>AC</given-names></name><name name-style="western"><surname>de Klerk</surname><given-names>JB</given-names></name><etal></etal></person-group>
<article-title>Genetic basis of hyperlysinemia</article-title>. <source/>Orphanet J Rare Dis<year>2013</year>; <volume>8</volume>: <fpage>57</fpage>.<pub-id pub-id-type="pmid">23570448</pub-id></mixed-citation>
</ref>
<ref id="aww221-B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>MF</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pagnamenta</surname><given-names>AT</given-names></name><name name-style="western"><surname>Daumer-Haas</surname><given-names>C</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>B</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Mutations in PGAP3 impair GPI-anchor maturation, causing a subtype of hyperphosphatasia with mental retardation</article-title>. <source/>Am J Hum Genet<year>2014</year>; <volume>94</volume>: <fpage>278</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">24439110</pub-id></mixed-citation>
</ref>
<ref id="aww221-B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kammermeier</surname><given-names>J</given-names></name><name name-style="western"><surname>Drury</surname><given-names>S</given-names></name><name name-style="western"><surname>James</surname><given-names>CT</given-names></name><name name-style="western"><surname>Dziubak</surname><given-names>R</given-names></name><name name-style="western"><surname>Ocaka</surname><given-names>L</given-names></name><name name-style="western"><surname>Elawad</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Targeted gene panel sequencing in children with very early onset inflammatory bowel disease—evaluation and prospective analysis</article-title>. <source/>J Med Genet<year>2014</year>; <volume>51</volume>: <fpage>748</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">25194001</pub-id></mixed-citation>
</ref>
<ref id="aww221-B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Krawitz</surname><given-names>PM</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Riess</surname><given-names>A</given-names></name><name name-style="western"><surname>Hietala</surname><given-names>M</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>U</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>PGAP2 mutations, affecting the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation syndrome</article-title>. <source/>Am J Hum Genet<year>2013</year>; <volume>92</volume>: <fpage>584</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23561847</pub-id></mixed-citation>
</ref>
<ref id="aww221-B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>W</given-names></name><name name-style="western"><surname>Kruse</surname><given-names>B</given-names></name><name name-style="western"><surname>Naidu</surname><given-names>S</given-names></name><name name-style="western"><surname>Bergin</surname><given-names>A</given-names></name><name name-style="western"><surname>Edwin</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>MR findings in adult-onset adrenoleukodystrophy</article-title>. <source/>AJNR Am J Neuroradiol<year>1995</year>; <volume>16</volume>: <fpage>1227</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">7677014</pub-id></mixed-citation>
</ref>
<ref id="aww221-B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JA</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>K</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>SW</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>CA</given-names></name><name name-style="western"><surname>Stankiewicz</surname><given-names>P</given-names></name><name name-style="western"><surname>Lupski</surname><given-names>JR</given-names></name></person-group>
<article-title>Role of genomic architecture in PLP1 duplication causing Pelizaeus-Merzbacher disease</article-title>. <source/>Hum Mol Genet<year>2006</year>; <volume>15</volume>: <fpage>2250</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">16774974</pub-id></mixed-citation>
</ref>
<ref id="aww221-B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Linnebank</surname><given-names>M</given-names></name><name name-style="western"><surname>Tschiedel</surname><given-names>E</given-names></name><name name-style="western"><surname>Haberle</surname><given-names>J</given-names></name><name name-style="western"><surname>Linnebank</surname><given-names>A</given-names></name><name name-style="western"><surname>Willenbring</surname><given-names>H</given-names></name><name name-style="western"><surname>Kleijer</surname><given-names>WJ</given-names></name><etal></etal></person-group>
<article-title>Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27 patients and a completed structure of the human ASL gene</article-title>. <source/>Hum Genet<year>2002</year>; <volume>111</volume>: <fpage>350</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">12384776</pub-id></mixed-citation>
</ref>
<ref id="aww221-B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>HC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>GE</given-names></name><name name-style="western"><surname>Pagnamenta</surname><given-names>AT</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Carvill</surname><given-names>GL</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis</article-title>. <source/>Hum Mol Genet<year>2014</year>; <volume>23</volume>: <fpage>3200</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">24463883</pub-id></mixed-citation>
</ref>
<ref id="aww221-B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mullaney</surname><given-names>JM</given-names></name><name name-style="western"><surname>Mills</surname><given-names>RE</given-names></name><name name-style="western"><surname>Pittard</surname><given-names>WS</given-names></name><name name-style="western"><surname>Devine</surname><given-names>SE</given-names></name></person-group>
<article-title>Small insertions and deletions (INDELs) in human genomes</article-title>. <source/>Hum Mol Genet<year>2010</year>; <volume>19</volume>: <fpage>R131</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">20858594</pub-id></mixed-citation>
</ref>
<ref id="aww221-B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nemeth</surname><given-names>AH</given-names></name><name name-style="western"><surname>Kwasniewska</surname><given-names>AC</given-names></name><name name-style="western"><surname>Lise</surname><given-names>S</given-names></name><name name-style="western"><surname>Parolin Schnekenberg</surname><given-names>R</given-names></name><name name-style="western"><surname>Becker</surname><given-names>EB</given-names></name><name name-style="western"><surname>Bera</surname><given-names>KD</given-names></name><etal></etal></person-group>
<article-title>Next generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model</article-title>. <source/>Brain<year>2013</year>; <volume>136</volume> (<issue>Pt 10</issue>): <fpage>3106</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">24030952</pub-id></mixed-citation>
</ref>
<ref id="aww221-B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pierson</surname><given-names>TM</given-names></name><name name-style="western"><surname>Adams</surname><given-names>D</given-names></name><name name-style="western"><surname>Bonn</surname><given-names>F</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>P</given-names></name><name name-style="western"><surname>Cherukuri</surname><given-names>PF</given-names></name><name name-style="western"><surname>Teer</surname><given-names>JK</given-names></name><etal></etal></person-group>
<article-title>Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases</article-title>. <source/>PLoS Genet<year>2011</year>; <volume>7</volume>: <fpage>e1002325</fpage>.<pub-id pub-id-type="pmid">22022284</pub-id></mixed-citation>
</ref>
<ref id="aww221-B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Reichardt</surname><given-names>JK</given-names></name><name name-style="western"><surname>Belmont</surname><given-names>JW</given-names></name><name name-style="western"><surname>Levy</surname><given-names>HL</given-names></name><name name-style="western"><surname>Woo</surname><given-names>SL</given-names></name></person-group>
<article-title>Characterization of two missense mutations in human galactose-1-phosphate uridyltransferase: different molecular mechanisms for galactosemia</article-title>. <source/>Genomics<year>1992</year>; <volume>12</volume>: <fpage>596</fpage>–<lpage>600</lpage>.<pub-id pub-id-type="pmid">1373122</pub-id></mixed-citation>
</ref>
<ref id="aww221-B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Reichardt</surname><given-names>JK</given-names></name><name name-style="western"><surname>Packman</surname><given-names>S</given-names></name><name name-style="western"><surname>Woo</surname><given-names>SL</given-names></name></person-group>
<article-title>Molecular characterization of two galactosemia mutations: correlation of mutations with highly conserved domains in galactose-1-phosphate uridyl transferase</article-title>. <source/>Am J Hum Genet<year>1991</year>; <volume>49</volume>: <fpage>860</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">1897530</pub-id></mixed-citation>
</ref>
<ref id="aww221-B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>S</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>N</given-names></name><name name-style="western"><surname>Bale</surname><given-names>S</given-names></name><name name-style="western"><surname>Bick</surname><given-names>D</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Gastier-Foster</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source/>Genet Med<year>2015</year>; <volume>17</volume>: <fpage>405</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
</ref>
<ref id="aww221-B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Saitsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>T</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>K</given-names></name><name name-style="western"><surname>Kodera</surname><given-names>H</given-names></name><name name-style="western"><surname>Kumada</surname><given-names>S</given-names></name><name name-style="western"><surname>Sugai</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title><italic>De novo</italic> mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood</article-title>. <source/>Nat Genet<year>2013</year>; <volume>45</volume>: <fpage>445</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23435086</pub-id></mixed-citation>
</ref>
<ref id="aww221-B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Santer</surname><given-names>R</given-names></name><name name-style="western"><surname>Rischewski</surname><given-names>J</given-names></name><name name-style="western"><surname>von Weihe</surname><given-names>M</given-names></name><name name-style="western"><surname>Niederhaus</surname><given-names>M</given-names></name><name name-style="western"><surname>Schneppenheim</surname><given-names>S</given-names></name><name name-style="western"><surname>Baerlocher</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>The spectrum of aldolase B (ALDOB) mutations and the prevalence of hereditary fructose intolerance in Central Europe</article-title>. <source/>Hum Mutat<year>2005</year>; <volume>25</volume>: <fpage>594</fpage>.</mixed-citation>
</ref>
<ref id="aww221-B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Saudi Mendelian Group</surname></name></person-group>
<article-title>Comprehensive gene panels provide advantages over clinical exome sequencing for Mendelian diseases</article-title>. <source/>Genome Biol<year>2015</year>; <volume>16</volume>: <fpage>134</fpage>.<pub-id pub-id-type="pmid">26112015</pub-id></mixed-citation>
</ref>
<ref id="aww221-B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>K</given-names></name><name name-style="western"><surname>Gadomski</surname><given-names>T</given-names></name><name name-style="western"><surname>Kozicz</surname><given-names>T</given-names></name><name name-style="western"><surname>Morava</surname><given-names>E</given-names></name></person-group>
<article-title>Congenital disorders of glycosylation: new defects and still counting</article-title>. <source/>J Inherit Metab Dis<year>2014</year>; <volume>37</volume>: <fpage>609</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">24831587</pub-id></mixed-citation>
</ref>
<ref id="aww221-B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sedel</surname><given-names>F</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>N</given-names></name><name name-style="western"><surname>Turpin</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lyon-Caen</surname><given-names>O</given-names></name><name name-style="western"><surname>Saudubray</surname><given-names>JM</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D</given-names></name></person-group>
<article-title>Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults</article-title>. <source/>J Inherit Metab Dis<year>2007</year>; <volume>30</volume>: <fpage>631</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">17694356</pub-id></mixed-citation>
</ref>
<ref id="aww221-B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>JV</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YT</given-names></name></person-group>
<article-title>Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle</article-title>. <source/>J Clin Invest<year>1996</year>; <volume>98</volume>: <fpage>352</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">8755644</pub-id></mixed-citation>
</ref>
<ref id="aww221-B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sloan</surname><given-names>JL</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Manoli</surname><given-names>I</given-names></name><name name-style="western"><surname>Chandler</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Krause</surname><given-names>C</given-names></name><name name-style="western"><surname>Carrillo-Carrasco</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Exome sequencing identifies ACSF3 as a cause of combined malonic and methylmalonic aciduria</article-title>. <source/>Nat Genet<year>2011</year>; <volume>43</volume>: <fpage>883</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">21841779</pub-id></mixed-citation>
</ref>
<ref id="aww221-B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sommen</surname><given-names>M</given-names></name><name name-style="western"><surname>Schrauwen</surname><given-names>I</given-names></name><name name-style="western"><surname>Vandeweyer</surname><given-names>G</given-names></name><name name-style="western"><surname>Boeckx</surname><given-names>N</given-names></name><name name-style="western"><surname>Corneveaux</surname><given-names>JJ</given-names></name><name name-style="western"><surname>van den Ende</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>DNA diagnostics of hereditary hearing loss: a targeted resequencing approach combined with a mutation classification system</article-title>. <source/>Hum Mutat<year>2016</year>; <volume>37</volume>: <fpage>812</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">27068579</pub-id></mixed-citation>
</ref>
<ref id="aww221-B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Almomani</surname><given-names>R</given-names></name><name name-style="western"><surname>Breedveld</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Santen</surname><given-names>GW</given-names></name><name name-style="western"><surname>Aten</surname><given-names>E</given-names></name><name name-style="western"><surname>Lefeber</surname><given-names>DJ</given-names></name><etal></etal></person-group>
<article-title>Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease)</article-title>. <source/>Hum Mutat<year>2013</year>; <volume>34</volume>: <fpage>706</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">23418007</pub-id></mixed-citation>
</ref>
<ref id="aww221-B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Trump</surname><given-names>N</given-names></name><name name-style="western"><surname>McTague</surname><given-names>A</given-names></name><name name-style="western"><surname>Brittain</surname><given-names>H</given-names></name><name name-style="western"><surname>Papandreou</surname><given-names>A</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>E</given-names></name><name name-style="western"><surname>Ngoh</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis</article-title>. <source/>J Med Genet<year>2016</year>; <volume>53</volume>: <fpage>310</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">26993267</pub-id></mixed-citation>
</ref>
<ref id="aww221-B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Berge</surname><given-names>L</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>EM</given-names></name><name name-style="western"><surname>Linnankivi</surname><given-names>T</given-names></name><name name-style="western"><surname>Uziel</surname><given-names>G</given-names></name><name name-style="western"><surname>Steenweg</surname><given-names>ME</given-names></name><name name-style="western"><surname>Isohanni</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: clinical and genetic characterization and target for therapy</article-title>. <source/>Brain<year>2014</year>; <volume>137</volume> (<issue>Pt 4</issue>): <fpage>1019</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">24566671</pub-id></mixed-citation>
</ref>
<ref id="aww221-B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Kuilenburg</surname><given-names>AB</given-names></name><name name-style="western"><surname>Dobritzsch</surname><given-names>D</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>J</given-names></name><name name-style="western"><surname>Meinsma</surname><given-names>R</given-names></name><name name-style="western"><surname>Benoist</surname><given-names>JF</given-names></name><name name-style="western"><surname>Assmann</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Dihydropyrimidinase deficiency: phenotype, genotype and structural consequences in 17 patients</article-title>. <source/>Biochim Biophys Acta<year>2010</year>; <volume>1802</volume>: <fpage>639</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">20362666</pub-id></mixed-citation>
</ref>
<ref id="aww221-B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Verity</surname><given-names>C</given-names></name><name name-style="western"><surname>Winstone</surname><given-names>AM</given-names></name><name name-style="western"><surname>Stellitano</surname><given-names>L</given-names></name><name name-style="western"><surname>Will</surname><given-names>R</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>A</given-names></name></person-group>
<article-title>The epidemiology of progressive intellectual and neurological deterioration in childhood</article-title>. <source/>Arch Dis Child<year>2010</year>; <volume>95</volume>: <fpage>361</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">19948513</pub-id></mixed-citation>
</ref>
<ref id="aww221-B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Walters-Sen</surname><given-names>LC</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Thrush</surname><given-names>DL</given-names></name><name name-style="western"><surname>Reshmi</surname><given-names>S</given-names></name><name name-style="western"><surname>Gastier-Foster</surname><given-names>JM</given-names></name><name name-style="western"><surname>Astbury</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Variability in pathogenicity prediction programs: impact on clinical diagnostics</article-title>. <source/>Mol Genet Genomic Med<year>2015</year>; <volume>3</volume>: <fpage>99</fpage>–<lpage>110</lpage>.<pub-id pub-id-type="pmid">25802880</pub-id></mixed-citation>
</ref>
<ref id="aww221-B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wohlers</surname><given-names>TM</given-names></name><name name-style="western"><surname>Christacos</surname><given-names>NC</given-names></name><name name-style="western"><surname>Harreman</surname><given-names>MT</given-names></name><name name-style="western"><surname>Fridovich-Keil</surname><given-names>JL</given-names></name></person-group>
<article-title>Identification and characterization of a mutation, in the human UDP-galactose-4-epimerase gene, associated with generalized epimerase-deficiency galactosemia</article-title>. <source/>Am J Hum Genet<year>1999</year>; <volume>64</volume>: <fpage>462</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">9973283</pub-id></mixed-citation>
</ref>
<ref id="aww221-B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wortmann</surname><given-names>SB</given-names></name><name name-style="western"><surname>Vaz</surname><given-names>FM</given-names></name><name name-style="western"><surname>Gardeitchik</surname><given-names>T</given-names></name><name name-style="western"><surname>Vissers</surname><given-names>LE</given-names></name><name name-style="western"><surname>Renkema</surname><given-names>GH</given-names></name><name name-style="western"><surname>Schuurs-Hoeijmakers</surname><given-names>JH</given-names></name><etal></etal></person-group>
<article-title>Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness</article-title>. <source/>Nat Genet<year>2012</year>; <volume>44</volume>: <fpage>797</fpage>–<lpage>802</lpage>.<pub-id pub-id-type="pmid">22683713</pub-id></mixed-citation>
</ref>
<ref id="aww221-B41">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Muzny</surname><given-names>DM</given-names></name><name name-style="western"><surname>Xia</surname><given-names>F</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Person</surname><given-names>R</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name><etal></etal></person-group>
<article-title>Molecular findings among patients referred for clinical whole-exome sequencing</article-title>. <source/>JAMA<year>2014</year>; <volume>312</volume>: <fpage>1870</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">25326635</pub-id></mixed-citation>
</ref>
<ref id="aww221-B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yohe</surname><given-names>S</given-names></name><name name-style="western"><surname>Hauge</surname><given-names>A</given-names></name><name name-style="western"><surname>Bunjer</surname><given-names>K</given-names></name><name name-style="western"><surname>Kemmer</surname><given-names>T</given-names></name><name name-style="western"><surname>Bower</surname><given-names>M</given-names></name><name name-style="western"><surname>Schomaker</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Clinical validation of targeted next-generation sequencing for inherited disorders</article-title>. <source/>Arch Pathol Lab Med<year>2015</year>; <volume>139</volume>: <fpage>204</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">25611102</pub-id></mixed-citation>
</ref>
<ref id="aww221-B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>A</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Manya</surname><given-names>H</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kano</surname><given-names>H</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1</article-title>. <source/>Dev Cell<year>2001</year>; <volume>1</volume>: <fpage>717</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">11709191</pub-id></mixed-citation>
</ref>
<ref id="aww221-B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>WW</given-names></name><name name-style="western"><surname>Froese</surname><given-names>DS</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>PE</given-names></name></person-group>
<article-title>The role of protein structural analysis in the next generation sequencing era</article-title>. <source/>Top Curr Chem<year>2014</year>; <volume>336</volume>: <fpage>67</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">22610134</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>